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Dr. Miura’s study evaluated the use of zonisamide
in children with cryptogenic localization-related
epilepsy, as monotherapy in a single daily dose. All
patients were naive to anticonvulsant therapy. The
study examined both clinical effects and pharma-
cokinetic effects of zonisamide. Patients ranged in
age from infancy (3 months) to 15 years of age,
with a mean age of 8 years. All were of normal
intelligence and did not have concomitant psychi-
atric illnesses. Thus, the group was homogeneous.
Earlier studies had shown that the plasma con-
centration of zonisamide peaks at 4 h, and that
its half-life in healthy volunteers is about 60 h.
These ﬁndings were the groundwork for examining
whether single-dose monotherapy of zonisamide is
effective for epilepsy treatment. Patients received
zonisamide in the morning at an initial dose of
2mg/kg per day, which was increased incrementally
to an 8mg/kg per day maintenance dose. Blood
samples were taken to determine trough and peak
plasma levels of the drug. Pharmacokinetic stud-
ies showed plasma level-to-dose ratios increased
with age, but peak-to-trough plasma level ratios
did not.
Dr. Miura and colleagues found that 57 of the 72
patients (79%) achieved complete seizure control
over a treatment period of 6–43 months (mean 27
months). Efﬁcacy data showed that the therapeu-
tic range is somewhere from 15 to 40g/mL, with
15g/mL being subtherapeutic for seizure control
in many, and 40g/mL being toxic in others. Low
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plasma levels of zonisamide explained why some
patients’ seizures were not controlled, but for oth-
ers, increasing zonisamide levels did not improve
seizure control.
Adverse effects of note were drowsiness and
ataxia, which are seen with many other antiepilep-
tic drugs (AEDs); and anorexia, which is also seen
with two of the newer AEDs—felbamate and top-
iramate. One patient experienced a rash with
agranulocytosis early in treatment; again, this has
been seen with other AEDs. Overall, the number
of patients who experienced adverse events with
monotherapy was small; nevertheless, it is impor-
tant to recognize the potential for such events.
For patients whose seizures were uncontrolled
with zonisamide (n = 12), carbamazepine was
added to the treatment regimen. Pharmacoki-
netic data showed that carbamazepine reduced
zonisamide plasma levels, consistent with the
cytochrome-inducing capacity of carbamazepine.
However, zonisamide had no impact on carba-
mazepine levels.
Of the 12 patients whose seizures were not
controlled by zonisamide monotherapy despite an
increase in dose, six became seizure-free with the
addition of carbamazepine. Seizures were con-
trolled in three additional patients by switching to
other anticonvulsants—valproate or clonazepam.
For the remaining three patients, seizures re-
mained refractory.
In summary, Dr. Miura’s study shows that zon-
isamide is effective as single-dose monotherapy
in young patients with cryptogenic localization-
related epilepsy. However, proper dosage must
be determined on a case-by-case basis, as is true
1059-1311/$30 — see front matter © 2004 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.seizure.2004.04.013
Commentary on Miura S25
with other AEDs. Zonisamide dosage should be
determined with attention to plasma levels that
may be too low and potentially subtherapeutic,
or too high and therefore toxic. In addition, al-
though adjunctive treatment with carbamazepine
can improve seizure control in patients for whom
zonisamide monotherapy is ineffective, physicians
should be aware that cytochrome inducers such as
carbamazepine will affect zonisamide levels and
potentially seizure control.
